Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) of the gastrointestinal tract that affects the mucosal lining of the colon. It commonly occurs in people aged between 15 years and 30 years. Ulcerative colitis is one of the two major types of IBD along with Crohn’s disease. Unlike Crohn’s disease, which can affect any part of the gastrointestinal tract, ulcerative colitis characteristically involves only the large bowel. The actual cause of the disease is still unidentified. However, the available information suggests that it may be the result of an over reactive immune response to normal bacteria and other substances in the gastrointestinal tract. The prominent symptoms of ulcerative colitis are abdominal pain and bloody diarrhea due to inflammation and the development of open sores (ulcers) in the large intestine (colon) and rectum. Other symptoms of ulcerative colitis include abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and fatigue. Severe complications of ulcerative colitis include hemorrhage, colon rupture, and the possible development of colon cancer. About 20% of people with ulcerative colitis have a family member with the disease or with Crohn’s disease, which is also a type of IBD. There is no known cure for ulcerative colitis till now. However, therapies are available that may significantly reduce the signs and symptoms of ulcerative colitis and even bring about a long-term remission.
The global ulcerative colitis therapeutics market is expected to expand substantially due to a rise in the prevalence of ulcerative colitis and increase in research and development to develop innovative treatment for ulcerative colitis. However, patent expiry of drugs and stringent government rules and regulations for approval of biosimilars are likely to constrain ulcerative colitis therapeutics market growth. Unmet needs in the treatment of ulcerative colitis are estimated to provide lucrative growth opportunities for the ulcerative colitis therapeutics market.
The global ulcerative colitis therapeutics market can be segmented based on drug class, distribution channel, and geography. Based on drug class, the global ulcerative colitis therapeutics market can be divided into aminosalicylates (sulfasalazine, mesalamine, and others), corticosteroids (prednisone, methylprednisolone), immunomodulators, antibiotics (ampicillin, ciprofloxacin), and others. In terms of distribution channels, the ulcerative colitis therapeutics market can be classified into hospital pharmacies, retail pharmacies, and online sales.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2185
Based on geography, the ulcerative colitis therapeutics market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The ulcerative colitis therapeutics market in each geography is sub-segmented into specific countries such as the U.S., Canada, the U.K., Germany, Brazil, China, India, and GCC countries. North America dominated the global ulcerative colitis therapeutics market because of the prevalence of ulcerative colitis and increase in demand for innovative medical technology. In the U.S., ulcerative colitis affects approximately 250,000 to 500,000 individuals, with an incidence of 8 to 12 per 100,000 persons annually, which has remained constant over the past five decades. Asia Pacific is expected to be a highly attractive region of the over the forecast period, due to an increase in health care awareness and rise in demand for advanced medical technology.
Key players operating in ulcerative colitis therapeutics market are AbbVie, Takeda Pharmaceuticals, Roche, Teva Pharmaceutical Industries Ltd., Johnson and Johnson, AstraZeneca, Shire Pharmaceuticals, Pfizer, Merck, and other prominent players. In order to gain a competitive advantage in the industry, the major players are actively involved in various growth strategies. Collaborations, agreements, partnerships, and new product launches are some of the important strategies applied by market players. In May 2018, Takeda Pharmaceutical Company Limited and Shire plc signed an agreement for the development of innovative gastrointestinal disease products.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453